Shield Therapeutics plc (LON:STX – Get Free Report) shares crossed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of GBX 3.03 ($0.04) and traded as low as GBX 2.70 ($0.03). Shield Therapeutics shares last traded at GBX 2.80 ($0.04), with a volume of 416,748 shares.
Shield Therapeutics Stock Performance
The business has a 50-day moving average of GBX 2.96 and a 200 day moving average of GBX 3.14. The company has a market cap of £21.12 million, a PE ratio of -67.50 and a beta of 1.42. The company has a debt-to-equity ratio of 3,691.50, a current ratio of 1.05 and a quick ratio of 2.16.
About Shield Therapeutics
Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.
Further Reading
- Five stocks we like better than Shield Therapeutics
- Stock Splits, Do They Really Impact Investors?
- Buffett Takes the Bait; Berkshire Buys More Oxy in December
- 3 Monster Growth Stocks to Buy Now
- Top 3 ETFs to Hedge Against Inflation in 2025
- Low PE Growth Stocks: Unlocking Investment Opportunities
- These 3 Chip Stock Kings Are Still Buys for 2025
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
